ARTICLE | Clinical News

Halaven eribulin mesylate regulatory update

January 12, 2015 8:00 AM UTC

Eisai said NHS England removed breast cancer drug Halaven eribulin mesylate from the Cancer Drugs Fund (CDF), making it the first disclosed drug to lose CDF coverage. The fund is intended to give patients access to drugs that would not otherwise be available on the NHS. The synthetic analog of halichondrin Beta is approved in the EU to treat locally advanced or metastatic breast cancer in patients whose disease has progressed after >=1 chemotherapy regimens for advanced disease. ...